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that approximately one in ten had had to change their employment status in order to 
look after the patient, usually a reduction in the number of hours worked. Half of the 
caregivers who had reduced their work hours reported a subsequent loss in income 
(ranging from a575 per month in France to a170 in the UK). 113 caregivers (13%) 
indicated that they receive medication to treat a condition brought on or exacerbated 
by their caregiver role, most frequently anxiety, depression and/or insomnia. Care-
givers also reported signiﬁcant impact on their social lives with 51% recording 
reduction in time available for themselves, 48% indicating a decrease in social activi-
ties and a quarter mentioning reduced ﬁtness. CONCLUSIONS: Caregiving is asso-
ciated with reduced employment and a negative ﬁnancial impact. It may result in 
less free time, social activity, poorer health due to reduced ﬁtness and increased 
medication. The emotional burden of seeing a loved-one suffer is high; however, the 
ﬁnancial and physical health implications of being a caregiver should not be 
underestimated.
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OBJECTIVES: Health plans calculate daily average consumption (DACON) to 
compare utilization and costs-per-day of therapy across medications with similar 
therapeutic indications. The purpose of this study is to examine DACON for dulox-
etine across its US-approved indications in major depressive disorder (MDD), general-
ized anxiety disorder (GAD), diabetic peripheral neuropathic pain (DPNP), and 
ﬁbromyalgia (FM) and to compare these results with those for venlafaxine-XR and 
pregabalin. METHODS: A retrospective analysis of commercially insured patients 
from large US health plans receiving q1 prescription for duloxetine, venlafaxine-XR, 
or pregabalin during 2006 and 2007 was conducted. MDD and GAD patient sub-
groups were constructed for duloxetine and venlafaxine-XR and DPNP and FM for 
duloxetine and pregabalin. Subgroup assignments were based on ICD-9 diagnosis 
codes recorded during the 12 months prior to the ﬁrst prescription for each index 
medication during the study interval. DACON was calculated by dividing total units 
dispensed by total days of supply. Units-per-day were converted to costs-per-day using 
June 2009 new wholesale prices.1 RESULTS: A total of 79,119 duloxetine, 97,369 
venlafaxine-XR, and 50,512 pregabalin patients were included in the 2007 analysis. 
DACON for duloxetine was 1.31 capsules per day, ranging between 1.27 for DPNP, 
1.33 for GAD, 1.39 for FM, and 1.52 for MDD. Average daily cost for duloxetine 
was $5.20 varying from $5.07 (DPNP) to $6.06 (MDD). DACONs for venlafaxine-
XR and pregabalin were 1.61 and 2.49, respectively. Duloxetine and pregabalin had 
similar average daily costs among patients with DPNP or FM, while the numbers were 
signiﬁcantly lower for duloxetine than venlafaxine-XR among patients with MDD or 
GAD. Results for 2006 were similar. CONCLUSIONS: Duloxetine has stable DACON 
across disease states and over time. Average daily costs were similar for duloxetine 
and pregabalin, but better for duloxetine versus venlafaxine-XR. 1First DataBank’s 
National Drug Data File™ accessed via Analysource Online, June, 2009.
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OBJECTIVES: The academic area of the Tertiary Education constitutes an important 
ﬁeld of adjustment and transaction of the young in the post adolescence age with 
particular tensions, pressures and stress. The objectives of this study are to focus on 
the extent of drug use in this student community and the investigation of the relation-
ship between socioeconomic factors, toxic habits and drug use. METHODS: The 
sampling was selected out of a population of 27,930 students according to stratiﬁed 
sampling weighed by gender, department and semester. The sample size was 829 stu-
dents, that is sufﬁcient for the estimation of the proportion of users with a signiﬁcance 
level of 0.05. The questionnaire comprised 83 items concerning sociodemographic and 
economic characteristics, adjustment to the academic environment and use of sub-
stances. RESULTS: A total of 161 persons, (19.4%) have used drugs at least once. 
There are signiﬁcant differences (p  0.01) between users and non users concerning: 
gender, relations between parents, satisfaction on study, alcohol use, smoking, number 
of cigarettes/day, friends that are drug users, age of smoke beginners, spending the 
night. Discriminant analysis has indicated that the discriminant factors between depen-
dents/on a crucial phase, before dependence and non users are: friends that are drug 
users (0.707), alcohol use (0.627), age of smoke beginners (0.608), relationship 
between parents (0.392). CONCLUSIONS: It is evident the resulting relationship 
between illegal and legal psychotropic substances. Consequently, prevention policy 
should not ignore tobacco and alcohol use. Additionally it is evident the predominant 
role of the social environment in the use of substances.
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OBJECTIVES: Benzodiazepines (BZDs) as anxiolytics, sedatives and hypnotics are 
frequently prescribed in daily medical practice worldwide and their abuse also becomes 
a target of public health measures. Because frequent attenders to emergence depart-
ments (EDs) sometimes display different psychological features, the utilization pattern 
of BZDs among this group of patients deserves investigations. METHODS: The data 
sources came from the historical claims datasets of 1,000,000-person cohort 
(LHID2005) in 2007, offered by the National Health Insurance Research Database in 
Taiwan. BZDs were deﬁned as those drug items belonging to groups of N03AE, 
N05BA, N05CD and N05CF in the ATC (Anatomical Therapeutic Chemical) classi-
ﬁcation system. For each beneﬁciary, the annual numbers of visits to EDs of hospitals 
and ambulatory visits to practicing clinics and outpatient departments of hospitals 
(excluding visits to dentistry and traditional Chinese medicine) with BZDs prescrip-
tions in 2007 were calculated. RESULTS: Among the valid 962,768 beneﬁciaries of 
the 1,000,000-person cohort, 157,865 (16.4%) patients (96,004 females and 61,861 
males; mean age 52.0 o 17.8 [SD] years) had received BZDs during ambulatory visits 
and 156,259 (16.2%) patients (76,644 females and 79,615 males; mean age 38.5 o 
23.5 [SD] years) had visited EDs in 2007. Among the 806,509 beneﬁciaries who did 
not visit EDs in 2007, only 14.5% (n  116,554) had ever received BZDs at ambula-
tory visits during the year. In contrast, 26.4% (n  41,311) of the ED attenders had 
received BZDs: the percentage rose from 22.6% in one-time ED attenders to 78.8% 
in those having more than 12 ED visits in a year. CONCLUSIONS: The use of BZDs 
was strongly associated with ED visits in Taiwan. Further stratiﬁed analyses are 
required to elucidate this phenomenon.
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OBJECTIVES: Medicine abuse is deﬁned as the recurrent use of a medicine in a non-
medical manner for non-medicinal purposes. The potential for abuse of combination 
(polycomponent) analgesics is high. The primary aim was to detect the potential abuse 
of combination analgesics using a medicine claims database. METHODS: An analysis 
of the South African combination analgesic market was made. Thereafter, a retrospec-
tive, exposure-cohort drug utilisation study was conducted on a medicine claims 
database of a medical aid administrator. The medicine ﬁle contained 1,357,717 
records for 2007. RESULTS: From the analysis of the combination analgesics avail-
able, it was found that there were 21 Schedule 5 (prescription-only) tablet formula-
tions (trade names) containing the following identical active ingredients: 320 mg 
paracetamol, 8 mg codeine phosphate, 32 mg caffeine and 50 mg meprobamate. From 
the database study, a total of 145,372 analgesics were prescribed (36.82% were avail-
able without a prescription). Combination analgesics accounted for 30.21% of all 
analgesics prescribed (92,181 products at a cost of R2,784,484). Analgesics were often 
prescribed on an acute basis in excessive quantities, for example 200 tablets. Combina-
tion analgesic tablets and capsules were also often dispensed to children in large 
quantities. For example, 10 prescriptions for 100 tablets of an over-the-counter com-
bination analgesic and eight prescriptions for 100 capsules of a prescription-only 
combination analgesic, were dispensed to children under seven years, while a syrup 
(a more suitable dosage form) was available. There was furthermore concern about 
the quantities of analgesics prescribed to speciﬁc families and it was clear that if the 
medical aid beneﬁt of one family member was exhausted, the analgesic was claimed 
under another family member’s name. A number of prescribers were identiﬁed who 
were over-prescribing speciﬁc analgesics. CONCLUSIONS: A medical aid database 
can be used to detect analgesic abuse and guidelines to control abuse and cost were 
proposed.
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OBJECTIVES: Although health spending is well below the OECD average when con-
sidered as a share of GDP, Slovakias pharmaceutical expenditures accounts 32% of 
total health care budget. The accessibility and availability of innovative drugs is good. 
Mandatory HTA (pharmacoeconomy) is incorporated in all relevant legislation, MoH 
set the ofﬁcial threshold by l1  a18,000/QALY and l2  a26,500/QALY. METHODS: 
We have analysed the legislation and ofﬁcial reimbursement decisions and commentar-
ies, published by the MoH in 2009. We analysed the applicants documentation 
including pharmacoeconomic analysis, as a mandatory part of the application. 
RESULTS: The main drug reimbursement body—Categorisation committee of the 
MoH—and pharmacoeconomic advisory committee evaluated the applicants dossier 
for the drug agomelatine (Valdoxan®, Servier Slovakia) for the treatment of depres-
sion. The pharmacoeconomic part of the application fulﬁled all legislative aspects. The 
CUA analysis was taken from Swedish pharmacoeconomic model and extrapolated in 
Slovak environment. CMA in Slovak conditions shows lower drug costs for agomela-
